Rare Disease Drug Tavneos Recalled in Ireland Following EU Safety Review

Tavneos Autoimmune Drug Recalled in Ireland Following European Regulatory Revocation

The rare disease medication Tavneos, chemically known as avacopan and manufactured by Amgen, has been officially recalled across the Republic of Ireland. According to the Health Products Regulatory Authority, the August withdrawal follows a European Medicines Agency recommendation to revoke the treatment’s market authorization.

The Bottom Line

• Regulatory Action: The European Commission endorsed the European Medicines Agency’s market authorization revocation in early August, forcing immediate national withdrawals across European jurisdictions.
• Patient Impact: Approximately 60 patients in the Republic of Ireland had received the specialty therapy before wholesale distribution ceased on August 11.
• Global Safety Signals: Regulatory scrutiny escalated after Japanese distribution data from Kissei Pharmaceutical flagged 20 patient fatalities among more than 8,500 treated cases since 2022.

Distribution Halts and Regulatory Timelines Across European Jurisdictions

Regulatory friction for the avacopan compound intensified significantly over the summer months. In May, distribution partner Kissei Pharmaceutical disclosed safety monitoring metrics from Japan, revealing 20 deaths among a cohort exceeding 8,500 patients treated since 2022. While Amgen subsequently clarified that a direct causal relationship could not be definitively established for all reported fatalities, the raw safety signals triggered immediate oversight from continental watchdogs.

By July, the European Medicines Agency recommended the complete removal of the drug’s centralized marketing authorization. The European Commission formally endorsed this decision in early August. Regional supply chains reacted immediately. In the Republic of Ireland, pharmaceutical wholesalers stopped distributing Tavneos on August 11. Shortly thereafter, the Health Products Regulatory Authority instructed firms to execute a formal recall of all remaining stock left at the wholesale level.

The ripple effects quickly crossed international borders. France’s national medicines safety agency, ANSM, initiated a full batch recall of Tavneos on August 19. Meanwhile, the United Kingdom’s Medicines and Healthcare products Regulatory Agency launched an independent review of the drug’s benefits and risks in June, though British regulators have yet to issue a definitive ruling on the status of the drug within their jurisdiction.

Clinical Continuity for Irish Patients Facing Treatment Transitions

Prior to the European Medicines Agency recommendation, approximately 60 patients in Ireland were actively receiving Tavneos. The Health Products Regulatory Authority emphasized that the medication was strictly administered by expert consultants specializing in severe vascular inflammation conditions.

Photo: theukpulse.co.uk

Tavneos Regulatory and Distribution Timeline

Date / Period	Jurisdiction / Agency	Action Taken
May	Japan / Kissei Pharmaceutical	Disclosed 20 fatalities among 8,500 treated patients.
July	European Union / EMA	Recommended revocation of centralized market authorization.
Early August	European Commission	Formally endorsed the market withdrawal decision.
August 11	Republic of Ireland / Wholesalers	Ceased commercial distribution of Tavneos stock.
August 19	France / ANSM	Commenced nationwide recall of all available drug batches.

Health authorities have issued explicit guidance warning patients against discontinuing the medication abruptly. Because Tavneos targets severe autoimmune conditions characterized by vessel wall inflammation, regulatory officials noted that some specialists had already begun transitioning patients to alternative protocols under careful medical supervision before the wholesale freeze took effect.

Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute financial advice.